Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2008

01.03.2008 | Lab Investigation - human/animal tissue

Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model

verfasst von: Brad J. Stish, Seunguk Oh, Daniel A. Vallera

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

To improve activity of a recombinant IL-13 cytotoxin (CT) comprised of IL-13 spliced to truncated diphtheria toxin (DT390), epidermal growth factor (EGF) was added to the same single chain protein. This new recombinant bispecific CT, called DTEGF13, enhanced the killing potency against the human glioblastoma lines, U87MG (0.015 nM) and U118MG (0.02 nM). A similar enhancement was observed against the lung carcinoma cell line, Calu-3 (0.0018 nM). Enhanced activity could not be explained by an increased number of cytokines available for binding since a combination of monospecific DTEGF and DTIL13 did not cause the same enhanced activity. Enhanced activity was dependent on the presence of both cytokines on the same single chain molecule and killing was receptor specific since target receptor negative leukemia cells were unaffected by the highly selective DTEGF13 and cytotoxicity could be blocked with anti-EGFR and anti-IL-13 antibodies. In a xenograft flank tumor model, intratumoral injection of DTEGF13, but not monospecific DTEGF or DTIL13, significantly inhibited the growth of established U87 tumors in nude mice (P < 0.04). In this model, the human EGF and IL-13 components of DTEGF13 are reactive with mouse EGFR and IL-13R, respectively. These studies show that a new co-targeting agent that simultaneously recognizes EGFR and IL-13R is more effective than its monospecific counterparts and that DTEGF13 has therapeutic advantages for glioblastoma.
Literatur
1.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC et al (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC et al (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
2.
Zurück zum Zitat Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human Glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1:1253–1258PubMed Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human Glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1:1253–1258PubMed
3.
Zurück zum Zitat Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985–990PubMed Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985–990PubMed
4.
Zurück zum Zitat Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48:103–111PubMedCrossRef Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48:103–111PubMedCrossRef
5.
Zurück zum Zitat Husain SR, Joshi BH, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92:168–175 Husain SR, Joshi BH, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92:168–175
6.
Zurück zum Zitat Husain SR, Puri RK (2003) Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65:37–48PubMedCrossRef Husain SR, Puri RK (2003) Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65:37–48PubMedCrossRef
7.
Zurück zum Zitat Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002) Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97:846–852PubMedCrossRef Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002) Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97:846–852PubMedCrossRef
8.
Zurück zum Zitat Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, Frankel AE (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329–334PubMed Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, Frankel AE (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329–334PubMed
9.
Zurück zum Zitat Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, Frankel AE (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107–1114PubMedCrossRef Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, Frankel AE (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107–1114PubMedCrossRef
10.
Zurück zum Zitat Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, Frankel AE (2003) Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2:783–787PubMed Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, Frankel AE (2003) Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2:783–787PubMed
11.
Zurück zum Zitat Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245–250PubMedCrossRef Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245–250PubMedCrossRef
12.
Zurück zum Zitat Williams DP, Snider CE, Strom TB, Murphy JR (1990) Structure/function analysis of interleukin-2-toxin (DAB486-IL-2) fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885–11889PubMed Williams DP, Snider CE, Strom TB, Murphy JR (1990) Structure/function analysis of interleukin-2-toxin (DAB486-IL-2) fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885–11889PubMed
13.
Zurück zum Zitat Collier RJ (1975) Diphtheria toxin: mode of action and structure. Bacteriol Rev 39:54–85PubMed Collier RJ (1975) Diphtheria toxin: mode of action and structure. Bacteriol Rev 39:54–85PubMed
14.
Zurück zum Zitat Oppenheimer NJ, Bodley JW (1981) Diphtheria toxin. Site and configuration of ADP-ribosylation of diphamide in elongation factor 2. J Biol Chem 256:8579–8581PubMed Oppenheimer NJ, Bodley JW (1981) Diphtheria toxin. Site and configuration of ADP-ribosylation of diphamide in elongation factor 2. J Biol Chem 256:8579–8581PubMed
15.
Zurück zum Zitat Law CL, Sidorenko SP, Clark EA (1994) Regulation of lymphocyte activation by the cell surface molecule CD22. Immunol Today 15:442–449PubMedCrossRef Law CL, Sidorenko SP, Clark EA (1994) Regulation of lymphocyte activation by the cell surface molecule CD22. Immunol Today 15:442–449PubMedCrossRef
16.
Zurück zum Zitat Vallera DA, Todhunter D, Kuroki DW, Shu Y, Sicheneder A, Panoskaltsis-Mortari A, Vallera VD, Chen H (2005) Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 29:331–341PubMedCrossRef Vallera DA, Todhunter D, Kuroki DW, Shu Y, Sicheneder A, Panoskaltsis-Mortari A, Vallera VD, Chen H (2005) Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 29:331–341PubMedCrossRef
17.
Zurück zum Zitat Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P (1968) Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300–1310PubMed Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P (1968) Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300–1310PubMed
18.
Zurück zum Zitat Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PC, Neville DM Jr, Youle RJ (1983) Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512–515PubMedCrossRef Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PC, Neville DM Jr, Youle RJ (1983) Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512–515PubMedCrossRef
19.
Zurück zum Zitat Vallera DA, Taylor PA, Sprent J, Blazar BR (1994) The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatability complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249–256PubMedCrossRef Vallera DA, Taylor PA, Sprent J, Blazar BR (1994) The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatability complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249–256PubMedCrossRef
20.
Zurück zum Zitat Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Kersey JH (2004) Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 19:11–23PubMedCrossRef Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Kersey JH (2004) Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 19:11–23PubMedCrossRef
21.
Zurück zum Zitat McKenzie AN, Zurawski G (1995) Interleukin-13: characterization and biologic properties. Cancer Treat Res 80:367–378PubMed McKenzie AN, Zurawski G (1995) Interleukin-13: characterization and biologic properties. Cancer Treat Res 80:367–378PubMed
22.
Zurück zum Zitat Elleman TC, Domagala T, McKern NM, Nerrie M et al (2001) Identification of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 40:8930–8939PubMedCrossRef Elleman TC, Domagala T, McKern NM, Nerrie M et al (2001) Identification of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 40:8930–8939PubMedCrossRef
23.
Zurück zum Zitat Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in in-vivo in nude mice. Protein Eng 15:419–427PubMedCrossRef Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in in-vivo in nude mice. Protein Eng 15:419–427PubMedCrossRef
24.
Zurück zum Zitat Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94:597–606PubMed Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94:597–606PubMed
25.
Zurück zum Zitat Rustamzadeh E, Hall WA, Todhunter DA, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA (2006) Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 118:2594–601PubMedCrossRef Rustamzadeh E, Hall WA, Todhunter DA, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA (2006) Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 118:2594–601PubMedCrossRef
26.
Zurück zum Zitat Rustamzadeh E, Hall WA, Todhunter DA, Vallera VD, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA (2007) Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120:411–419PubMedCrossRef Rustamzadeh E, Hall WA, Todhunter DA, Vallera VD, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA (2007) Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120:411–419PubMedCrossRef
27.
Zurück zum Zitat Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK (2006) Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5:239–250. ReviewPubMed Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK (2006) Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5:239–250. ReviewPubMed
28.
Zurück zum Zitat Minty A, Chalon P, Derocq JM, Dumont X, Guillemont JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248–250PubMedCrossRef Minty A, Chalon P, Derocq JM, Dumont X, Guillemont JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248–250PubMedCrossRef
29.
Zurück zum Zitat McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S et al (1993) Interleukin 13, a T-cell derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 90:3735–3739PubMedCrossRef McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S et al (1993) Interleukin 13, a T-cell derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 90:3735–3739PubMedCrossRef
30.
Zurück zum Zitat Brown KD, Zurawski SM, Mosmann TR, Zurawski G (1989) A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142:679–687PubMed Brown KD, Zurawski SM, Mosmann TR, Zurawski G (1989) A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142:679–687PubMed
31.
Zurück zum Zitat Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19–26PubMedCrossRef Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19–26PubMedCrossRef
32.
Zurück zum Zitat Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, Verma IM, Gill GN, Rosenfeld MG (1984) Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 224:843–848PubMedCrossRef Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, Verma IM, Gill GN, Rosenfeld MG (1984) Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 224:843–848PubMedCrossRef
33.
Zurück zum Zitat Lo HW, Hung MC (2006) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94:184–188PubMedCrossRef Lo HW, Hung MC (2006) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94:184–188PubMedCrossRef
34.
Zurück zum Zitat Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs. 17:855–857PubMedCrossRef Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs. 17:855–857PubMedCrossRef
35.
Zurück zum Zitat Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20:15–25 Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20:15–25
36.
Zurück zum Zitat Zhen G, Park SW, Nguyenvu LT, Rodriguez MW et al (2007) Interleukin-13 and EGF receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 36:244–253 Epub 2006PubMedCrossRef Zhen G, Park SW, Nguyenvu LT, Rodriguez MW et al (2007) Interleukin-13 and EGF receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 36:244–253 Epub 2006PubMedCrossRef
37.
Zurück zum Zitat Wu AH, Low WC (2002) Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues. J Neurooncol 59:99–105PubMedCrossRef Wu AH, Low WC (2002) Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues. J Neurooncol 59:99–105PubMedCrossRef
38.
Zurück zum Zitat Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058–3067PubMedCrossRef Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058–3067PubMedCrossRef
39.
Zurück zum Zitat Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H (2005) A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 11:3879–3888PubMedCrossRef Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H (2005) A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 11:3879–3888PubMedCrossRef
40.
Zurück zum Zitat Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA (2004) A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157–164 Epub 2004PubMedCrossRef Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA (2004) A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157–164 Epub 2004PubMedCrossRef
41.
Zurück zum Zitat Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 13:6486–6493PubMedCrossRef Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 13:6486–6493PubMedCrossRef
Metadaten
Titel
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model
verfasst von
Brad J. Stish
Seunguk Oh
Daniel A. Vallera
Publikationsdatum
01.03.2008
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2008
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9499-8

Weitere Artikel der Ausgabe 1/2008

Journal of Neuro-Oncology 1/2008 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.